[go: up one dir, main page]

AR111971A1 - METHODS FOR TREATING PATIENTS WITH FABRY'S DISEASE WHO HAVE KIDNEY FAILURE - Google Patents

METHODS FOR TREATING PATIENTS WITH FABRY'S DISEASE WHO HAVE KIDNEY FAILURE

Info

Publication number
AR111971A1
AR111971A1 ARP180101424A ARP180101424A AR111971A1 AR 111971 A1 AR111971 A1 AR 111971A1 AR P180101424 A ARP180101424 A AR P180101424A AR P180101424 A ARP180101424 A AR P180101424A AR 111971 A1 AR111971 A1 AR 111971A1
Authority
AR
Argentina
Prior art keywords
methods
patient
fabry
disease
treating patients
Prior art date
Application number
ARP180101424A
Other languages
Spanish (es)
Inventor
Jeff Castelli
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of AR111971A1 publication Critical patent/AR111971A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proveen métodos para el tratamiento de la enfermedad de Fabry en un paciente que tiene insuficiencia renal y/o proteinuria elevada. Ciertos métodos comprenden administrar al paciente entre aproximadamente 100 y aproximadamente 150 mg de equivalente de base libre de migalastat o una sal del mismo, a una frecuencia de una vez, día por medio. Ciertos métodos también proveen la estabilización de la función renal, reduciendo el índice de masa ventricular izquierda, reduciendo la globotriaosilsfingosina en plasma y/o incrementando la actividad de la a-galactosidasa A en el paciente.Methods are provided for the treatment of Fabry disease in a patient who has renal failure and / or elevated proteinuria. Certain methods comprise administering to the patient between about 100 and about 150 mg of migalastat free base equivalent or a salt thereof, at a frequency of once every other day. Certain methods also provide stabilization of renal function, reducing the left ventricular mass index, reducing plasma globotriaosylsphingosine and / or increasing the activity of α-galactosidase A in the patient.

ARP180101424A 2017-05-30 2018-05-30 METHODS FOR TREATING PATIENTS WITH FABRY'S DISEASE WHO HAVE KIDNEY FAILURE AR111971A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762512458P 2017-05-30 2017-05-30

Publications (1)

Publication Number Publication Date
AR111971A1 true AR111971A1 (en) 2019-09-04

Family

ID=64662279

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101424A AR111971A1 (en) 2017-05-30 2018-05-30 METHODS FOR TREATING PATIENTS WITH FABRY'S DISEASE WHO HAVE KIDNEY FAILURE

Country Status (2)

Country Link
AR (1) AR111971A1 (en)
AU (1) AU2018220047A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021015352A (en) * 2019-06-11 2022-04-06 Amicus Therapeutics Inc METHODS TO TREAT FABRY DISEASE IN PATIENTS WHO HAVE KIDNEY FAILURE.

Also Published As

Publication number Publication date
AU2018220047A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
CO2019015026A2 (en) Treatment methods for patients with Fabry disease who have kidney failure
MX2023005455A (en) Methods of treating heart failure by administering omecamtiv mecarbil.
MX2024010140A (en) NEW METHODS.
CL2021003280A1 (en) Methods of treating Fabry disease in patients who have renal failure
CL2018001677A1 (en) Treatment of fabry disease in patients not treated and previously treated with ert
MX2020006284A (en) Bis-choline tetrathiomolybdate for treating wilson disease.
NI201100147A (en) METHODS TO TREAT ACUTE MYOCARDIAL INFARCTIONS AND RELATED DISORDERS.
CL2020000491A1 (en) Methods to increase and / or stabilize cardiac function in patients with Fabry disease.
MX2016000364A (en) METHODS TO TREAT OR PREVENT OPHTHALMOLOGICAL AFFECTIONS.
CL2011000798A1 (en) Use of dabigatran etexilate or a salt thereof to prepare a useful medication for the prevention of stroke in patients suffering from atrial fibrillation.
AR114392A1 (en) TREATMENT OF PATIENTS WITH CLASSIC FABRY DISEASE
MX2022003128A (en) METHODS OF TREATMENT OF NEURODEGENERATIVE DISORDERS IN A PARTICULAR POPULATION OF PATIENTS.
CL2011000806A1 (en) Use of dabigatran etexilate or a salt thereof to prepare a useful medication for the prevention of stroke in patients suffering from atrial fibrillation.
CL2022000786A1 (en) Treatment methods to modify hemodynamics
AR111374A1 (en) USE OF LIK066 IN PATIENTS WITH HEART FAILURE
MX379191B (en) NEW USE OF LANDIOLOL HYDROCHLORIDE IN THE LONG-TERM TREATMENT OF TACHYARRHYTHMIAS AND HYPERTENSION.
AR111971A1 (en) METHODS FOR TREATING PATIENTS WITH FABRY'S DISEASE WHO HAVE KIDNEY FAILURE
EP4327869A3 (en) Methods of treating fabry patients having renal impairment
MX370451B (en) Diethyl- [6- (4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl) - naphthalen-2-yl-methyl] -ammonium chloride for use in the treatment of muscular dystrophy.
MX2022006045A (en) Methods of administering voxelotor.
EA201992869A1 (en) WAYS OF TREATMENT OF PATIENTS WITH FABRY DISEASE, WHICH HAVE A KIDNEY FAILURE
MX2021007324A (en) Oral therapy using 6,8-bis-benzylthio-octanoic acid.
AR109102A1 (en) TREATMENT OF FABRY'S DISEASE IN PATIENTS NOT TREATED AND PREVIOUSLY TREATED WITH ERT
EA201991119A1 (en) PHARMACEUTICAL COMPOSITION, METHODS OF TREATMENT AND ITS APPLICATION